MARKET

NRBO

NRBO

Neurobo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4798
-0.0102
-2.08%
Pre Market: 0.4506 -0.0292 -6.09% 08:59 07/01 EDT
OPEN
0.4843
PREV CLOSE
0.4900
HIGH
0.4899
LOW
0.4600
VOLUME
299
TURNOVER
--
52 WEEK HIGH
5.63
52 WEEK LOW
0.3732
MARKET CAP
12.79M
P/E (TTM)
-0.7831
1D
5D
1M
3M
1Y
5Y
Zendesk, Quotient, + 40 Stocks Moving In Friday's Mid-Day Session
Gainers USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
Benzinga · 06/24 16:07
24 Stocks Moving in Tuesday's Pre-Market Session
Gainers Valneva SE (NASDAQ: VALN) shares rose 83.6% to $25.18  in pre-market trading following Pfizer agreement to acquire an 8.1% stake.
Benzinga · 06/21 10:04
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 05/31 12:19
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 05/10 16:01
30 Stocks Moving in Tuesday's Pre-Market Session
Gainers Vroom, Inc. (NASDAQ: VRM) shares rose 38% to $1.49 in pre-market trading after the company reported better-than-expected Q1 results.
Benzinga · 05/10 10:20
90 Biggest Movers From Yesterday
  Losers
Benzinga · 05/10 09:11
BRIEF-Neurobo Pharmaceuticals, Inc. Expands Management Team With The Appointment Of Matthew Bardin, Pharmd, Bcps As Senior Vice President Operations
reuters.com · 05/06 12:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 04/18 13:18
More
No Data
Learn about the latest financial forecast of NRBO. Analyze the recent business situations of Neurobo Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NRBO stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.
High16.00
Average16.00
Low16.00
Current 0.4700
EPS
Actual
Estimate
-0.34-0.25-0.17-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q1 2019
Institutional Holdings
Institutions: 37
Institutional Holdings: 4.01M
% Owned: 15.05%
Shares Outstanding: 26.66M
TypeInstitutionsShares
Increased
2
7.48K
New
4
54.43K
Decreased
7
345.46K
Sold Out
4
74.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.97%
Pharmaceuticals & Medical Research
+0.93%
Key Executives
Non-Executive Chairman/Independent Director
Andrew Koven
President/Chief Executive Officer
Ben Gil Price
Senior Vice President
Matthew Bardin
Director
Jeong Gu Kang
Independent Director
Jason Groves
Independent Director
Hyung Kim
Independent Director
Na Yeon Kim
Independent Director
Michael Salsbury
Independent Director
D. Gordon Strickland
No Data
No Data
About NRBO
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of therapeutics. It is focused on four therapeutics programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic disease. The Company’s therapeutics programs include ANA001, NB-01, NB-02 and Gemcabene. Its ANA001, is an oral niclosamide formulation and was developed as a treatment for patients with moderate coronavirus disease (COVID-19). NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy and treat a range of neuropathic conditions. Its NB-02, which treats the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition. The Company’s Gemcabene, which is being assessed as an acute indication for COVID-19 treatments.

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.